Immune-Mediated Necrotizing Myopathies: Current Landscape

Bohan A, Peter JB. Polymyositis and dermatomyositis 1. N Engl J Med. 1975;292(7):344–7.

Article  CAS  PubMed  Google Scholar 

Miller FW, et al. Polymyositis: an overdiagnosed entity. Neurology. 2004;63(2):402–402.

Article  CAS  PubMed  Google Scholar 

Watanabe Y, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry. 2016;87(10):1038–44.

Article  PubMed  Google Scholar 

Nakao Y, et al. A Novel antibody which precipitates 7.5s Rna is isolated from a patient with autoimmune-disease. Biochem Biophys Res Commun. 1982;109(4):1332–8.

Article  CAS  PubMed  Google Scholar 

Allenbach Y, et al. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689–701.

Article  CAS  PubMed  Google Scholar 

Miller T, et al. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry. 2002;73(4):420–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Christopher-Stine L, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mammen AL, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343(6257):425–30.

Article  CAS  PubMed  Google Scholar 

Morikawa S, et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb. 2005;12(3):121–31.

Article  CAS  PubMed  Google Scholar 

Werner JL, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum. 2012;64(12):4087–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Allenbach Y, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies. Medicine. 2014;93(3):150–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benveniste O, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011;63(7):1961–71.

Article  CAS  PubMed  Google Scholar 

Bergua C, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis. 2019;78(1):131–9.

Article  CAS  PubMed  Google Scholar 

Meyer A, et al. Incidence and prevalence of inflammatory myopathies: a systematic review. Rheumatology (Oxford). 2015;54(1):50–63.

Article  CAS  PubMed  Google Scholar 

•Shelly S, et al. Incidence and prevalence of immune-mediated necrotizing myopathy in adults in Olmsted County, Minnesota. Muscle Nerve. 2022;65:5, 541–546. This study identifies local prevalance of IMNM.

Kassardjian CD, et al. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol. 2015;72(9):996–1003.

Article  PubMed  Google Scholar 

Liang WC, et al. Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies. Rheumatology. 2017;56(2):287–93.

Article  PubMed  Google Scholar 

Wei J, Ketner E, Mammen AL. Increased risk of statin-associated autoimmune myopathy among American Indians. Arthritis Rheumatol. 2022;74(9):1602–3.

Article  PubMed  PubMed Central  Google Scholar 

Close RM, et al. Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies. Rheumatology. 2021;60(2):692–8.

Article  PubMed  Google Scholar 

Pinal-Fernandez I, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res. 2017;69(2):263–70.

Article  CAS  Google Scholar 

Pinal-Fernandez I, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res (Hoboken). 2017;69(2):263–70.

Article  CAS  PubMed  Google Scholar 

Mohassel P, et al. Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurol Neuroimmunol Neuroinflamm. 2019;6(1):e523.

Article  PubMed  Google Scholar 

•Hiebeler, M., et al., Slowly progressive limb-girdle weakness and hyperckemia - limb girdle muscular dystrophy or anti-3-hydroxy-3-methylglutaryl-CoA-reductase-myopathy? J Neuromuscul Dis. 2022;9:(5):607–614. This case report highlights diagnostic challenges in differentiating LGMD from slowly progressing forms of anti-HMGCR IMNM.

Suzuki S, Nishikawa A, Kuwana M, Nishimura H, Watanabe Y, Nakahara J, Hayashi YK, Suzuki N, Nishino I. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis. 2015;10:61. https://doi.org/10.1186/s13023-015-0277-y.

Trallero-Araguas E, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523–32.

Article  CAS  PubMed  Google Scholar 

Fiorentino DF, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum. 2013;65(11):2954–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

••Allenbach Y, et al. 224th ENMC International Workshop:: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14–16 October 2016. Neuromuscul Disord. 2018. 28(1):87–99. International panel which provided consensus characterization of IMNM clinicopathological, serological and therapeutic findings.

Allenbach Y, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain. 2016;139(Pt 8):2131–5.

Article  PubMed  Google Scholar 

Tiniakou E, Mammen AL. Idiopathic inflammatory myopathies and malignancy: a comprehensive review. Clin Rev Allergy Immunol. 2017;52(1):20–33.

Article  CAS  PubMed  Google Scholar 

Kadoya M, et al. Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm. 2016;3(6):e290.

Article  PubMed  PubMed Central  Google Scholar 

•Shelly S, et al. Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation. Rheumatology (Oxford). 2022;62:(1):281–289. This study of malignancy in IMNM with 5 year follow up did not find increased incidence compared to age matched controls.

•Mecoli CA, et al. Subsets of idiopathic inflammatory myositis enriched for contemporaneous cancer relative to the general population. Arthritis Rheumatol. 2023;75:(4):620–629. Contrary to the prior reference, this study with similar follow up showed an increased incidence of malignancy in IMNM

Manousakis G. Inflammatory myopathies. Continuum (Minneap Minn). 2022;28(6):1643–62.

PubMed  Google Scholar 

Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep. 2018;20(4):21.

Article  PubMed  PubMed Central  Google Scholar 

Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168(1):6–15.

Article  CAS  PubMed  Google Scholar 

Cholesterol Treatment Trialists, C. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832–45.

Article  Google Scholar 

Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C-60C.

Article  CAS  PubMed  Google Scholar 

Mammen AL. Statin-associated autoimmune myopathy. N Engl J Med. 2016;374(7):664–9.

Article  CAS  PubMed  Google Scholar 

Vladutiu GD, Isackson PJ. SLCO1B1 variants and statin-induced myopathy. N Engl J Med. 2009;360(3):304.

Article  CAS  PubMed  Google Scholar 

Grable-Esposito P, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185–90.

Article  CAS  PubMed  Google Scholar 

Caughey GE, et al. Association of statin exposure with histologically confirmed idiopathic inflammatory myositis in an australian population. JAMA Intern Med. 2018;178(9):1224–9.

Article  PubMed  PubMed Central  Google Scholar 

Mohassel P, Mammen AL. Anti-HMGCR myopathy. J Neuromuscul Dis. 2018;5(1):11–20.

Article  PubMed  PubMed Central  Google Scholar 

Alshehri A, et al. Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e124.

留言 (0)

沒有登入
gif